November 12th 2024
A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
The Expanding Role of 5-FU in Dermatology (PDF)
April 1st 2005Recently, a group of leading dermatologists, clinical investigators, and dermasurgeons met to discuss the role of 5-fluorouracil (5-FU) in their practices. The experts discussed a new treatment paradigm for actinic keratosis (AK) and how it is changing. They also shared their personal experiences in using 5-FU innovatively to treat AK, while reducing inflammation and discomfort and improving compliance. In addition, the physicians reviewed the use of 5-FU in the treatment of several other dermatologic conditions, such aswarts and actinic cheilitis.
Drug combination trumps single-agent acne treatment
March 1st 2005New Orleans — Combining a popular topical retinoid with a widely used antibiotic — and applying them at the same time as if they were one drug — clearly outperforms using either agent separately in treating acne, according to new data presented at the 63rd Annual Meeting of the American Academy of Dermatology (AAD) here.
Drug combination trumps single-agent acne treatment
February 21st 2005Combining a popular topical retinoid with a widely used antibiotic - and applying them at the same time as if they were one drug - clearly outperforms using either agent separately in treating acne. The key is adding to them a novel aqueous hydrogel which solubilizes the two old stand-by drugs and stabilizes them to provide a particularly effective once-daily treatment.
Silicone scar sheets minimize scar formation
February 20th 2005Silicone sheet technology has been clinically proven to improve the appearance of scars significantly and has been used by physicians for years, according to Pfizer who is displaying its Neosporin Scar Sheets here at the 63rd Annual Meeting.
Allergan introduces Prevage antioxidant cream
February 20th 2005Allergan, Inc., has launched Prevage, antioxidant cream, the first and only clinically tested antioxidant that not only reduces the appearance of fine lines and wrinkles, but also provides protection against environmental factors including sun damage, air pollution and cigarette smoke, says the company.
Neocutis introduces skin cream with growth factors
February 19th 2005Neocutis, San Francisco, is introducing Bio-restorative Skin Cream with PSP. PSP is a proprietary cosmetic ingredient developed at the University of Lausanne, Switzerland. It is the only cosmeceutical product containing the specific natural human growth factors, cytokines and enzymatic antioxidants associated with natural bio-restoration of the skin to promote scarless wound healing. According to the company, the unique formulation of PSP provides skin with the optimal balance of skin nutrients helping to preserve or restore skin when stressed.
Neocutis introduces skin cream with growth factors
February 19th 2005Neocutis, San Francisco, is introducing Bio-restorative Skin Cream with PSP. PSP is a proprietary cosmetic ingredient developed at the University of Lausanne, Switzerland. It is the only cosmeceutical product containing the specific natural human growth factors, cytokines and enzymatic antioxidants associated with natural bio-restoration of the skin to promote scarless wound healing. According to the company, the unique formulation of PSP provides skin with the optimal balance of skin nutrients helping to preserve or restore skin when stressed.
WaveLight Laser enters U.S. market
February 19th 2005WaveLight Laser Technolgie AG of Erlangen, Germany, is introducing three aesthetic lasers to the U.S. market at the 63rd Annual Meeting. Already used in Europe and Asia, the Sinon Q-switched ruby, the Mydon Nd:YAG and the Arion Alexandrite lasers will be Wavelight's first products to enter the U.S. market.
Botulinum toxin type A treatment of upper facial rhytids done safely, effectively in single session
February 19th 2005Botulinum toxin type A (Botox Cosmetic, Allergan) can be used safely and effectively in a range of doses to simultaneously treat a spectrum of upper facial rhytids in adult women, but a higher dose provides more marked and more durable efficacy without compromising safety, according to the results of a dose-comparison study presented by Alastair Carruthers, M.D., and Jean Carruthers, M.D.